Cisplatin-incorporating polymeric micelles (NC-6004) can reduce nephrotoxicity and neurotoxicity of cisplatin in rats
Open accessThe DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Abstract
In spite of the clinical usefulness of cisplatin (CDDP), there are many occasions in which it is difficult to continue the administration of CDDP due to its nephrotoxicity and neurotoxicity. We examined the incorporation of CDDP into polymeric micelles to see if this allowed the resolution of these disadvantages. Cisplatin was incorporated into polymeric micelles through the polymer-metal complex formation between polyethylene glycol poly(glutamic acid) block copolymers and CDDP (NC-6004). The pharmacokinetics, pharmacodynamics, and toxicity studies of CDDP and NC-6004 were conducted in rats or mice. The particle size of NC-6004 was approximately 30 nm, with a narrow size distribution. In rats, the area under the curve and total body clearance values for NC-6004 were 65-fold and one-nineteenth the values for CDDP (P<0.001 and 0.01, respectively). In MKN-45-implanted mice, NC-6004 tended to show antitumour activity, which was comparable to or greater than that of CDDP. Histopathological and biochemical studies revealed that NC-6004 significantly inhibited the nephrotoxicity of CDDP. On the other hand, blood biochemistry revealed transient hepatotoxicity on day 7 after the administration of NC-6004. Furthermore, rats given CDDP showed a significant delay (P<0.05) in sensory nerve conduction velocity in their hind paws as compared with rats given NC-6004. Electron microscopy in rats given CDDP indicated the degeneration of the sciatic nerve, but these findings were not seen in rats given NC-6004. These results were presumably attributable to the significantly reduced accumulation of platinum in nerve tissue when NC-6004 was administered (P<0.05). NC-6004 preserved the antitumour activity of CDDP and reduced its nephrotoxicity and neurotoxicity, which would therefore seem to suggest that NC-6004 could allow the long-term administration of CDDP where caution against hepatic dysfunction must be exercised.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“NC-6004 exhibited stable micelles in solution and slowly released cisplatin from the micelle for over 150 h in physiological saline. NC-6004 exhibited a narrow size distribution in solution with a size of 28 nm and loading of cisplatin in NC-6004 was up to 39% LC [153].”
From Polymeric micelles for the delivery of poorly soluble drugs: From nanoformulation to clinical approval. (2020) · cites this paper as [153]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“A similar polymeric micelle formulation where CDDP was coordinated with PEG-b-P(Glu) [153] evolved into a clinically evaluated polymeric micelle drug, NC-6004 which is described below in Section 5.3.”
From Polymeric micelles for the delivery of poorly soluble drugs: From nanoformulation to clinical approval. (2020) · cites this paper as [153]
The cited source says what the claim attributes to it.
In the citing paper
“Originally developed by Kataoka’s group and NanoCarrier Co., Ltd., NC-6004 is a cisplatin-containing polymeric micelle formed via coordination of platinum drug with the P(Glu) segment of the PEG-b-P(Glu) block copolymer (PEG: 12,000 g/mol and P(Glu): 6,000 g/mol) [153].”
From Polymeric micelles for the delivery of poorly soluble drugs: From nanoformulation to clinical approval. (2020) · cites this paper as [153]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Matsumura, Y., & Maeda, H. (1986) · PubMed · Cited by 6,781
Self-citationTumor vascular permeability and the EPR effect in macromolecular therapeutics: a review
Maeda, H., Wu, J., Sawa, T., Matsumura, Y., & Hori, K. (2000) · Journal of Controlled Release · doi:10.1016/s0168-3659(99)00248-5 · Cited by 6,565
Self-citationMaeda, H. (2001) · Advances in Enzyme Regulation · doi:10.1016/s0065-2571(00)00013-3 · Cited by 2,495 · cited 1×
“…polymers or nanoparticles, which are less prone to leak from intact vasculature, and which can be retained in solid tumour tissue for a longer time (enhanced permeability and retention effect (EPR) effect) (Matsumura and Maeda, 1986; Maeda and Matsumura, 1989; Maeda, 2000, 2001).”
BackgroundAmphipathic polyethyleneglycols effectively prolong the circulation time of liposomes
Klibanov, A. L., Maruyama, K., Torchilin, V. P., & Huang, L. (1990) · FEBS Letters · doi:10.1016/0014-5793(90)81016-h · Cited by 2,027 · cited 1×
“…93, 678 – 687 & 2005 Cancer Research UK All rights reserved 0007 – 0920/05 $30.00 www.bjcancer.com T ra n sla tio n a l T h e ra p e u tic s the reticuloendothelial system (RES) and to enhance the blood retention profile (Klibanov et al, 1990, 1991; Allen, 1994; Gabizon etal, 1996; Lasic, 1996).”
BackgroundInfluentialdu Bois, A. (2003) · CancerSpectrum Knowledge Environment · doi:10.1093/jnci/djg036 · Cited by 1,113 · cited 1×
“Consequently, these analogues are becoming the standard drugs for ovarian cancer (du Bois et al, 2003) and colon cancer (Cassidy et al, 2004).”
BackgroundNovel cisplatin-incorporated polymeric micelles can eradicate solid tumors in mice.
Nishiyama, N., Okazaki, S., Cabral, H., Miyamoto, M., Kato, Y., Sugiyama, Y., Nishio, K., Matsumura, Y., & Kataoka, K. (2003) · PubMed · Cited by 710
Self-citation(1998) · British Journal of Cancer · doi:10.1038/bjc.1998.1 · Cited by 654
Phase I clinical trial and pharmacokinetic evaluation of NK911, a micelle-encapsulated doxorubicin
Matsumura, Y., Hamaguchi, T., Ura, T., Muro, K., Yamada, Y., Shimada, Y., Shirao, K., Okusaka, T., Ueno, H., Ikeda, M., et al. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6602204 · Cited by 623 · cited 1×
“The Phase I clinical trial of adriamycin-incorporating polymeric micelles has been completed (Matsumura et al, 2004).”
BackgroundSelf-citationHamaguchi, T., Matsumura, Y., Suzuki, M., Shimizu, K., Goda, R., Nakamura, I., Nakatomi, I., Yokoyama, M., Kataoka, K., & Kakizoe, T. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602479 · Cited by 565
Self-citationCassidy, J., Tabernero, J., Twelves, C., Brunet, R., Butts, C., Conroy, T., Debraud, F., Figer, A., Grossmann, J., Sawada, N., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.11.069 · Cited by 525 · cited 1×
“Consequently, these analogues are becoming the standard drugs for ovarian cancer (du Bois et al, 2003) and colon cancer (Cassidy et al, 2004).”
BackgroundKlibanov, A. L., Maruyama, K., Beckerleg, A. M., Torchilin, V. P., & Huang, L. (1991) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/0005-2736(91)90385-l · Cited by 480 · cited 1×
“…93, 678 – 687 & 2005 Cancer Research UK All rights reserved 0007 – 0920/05 $30.00 www.bjcancer.com T ra n sla tio n a l T h e ra p e u tic s the reticuloendothelial system (RES) and to enhance the blood retention profile (Klibanov et al, 1990, 1991; Allen, 1994; Gabizon etal, 1996; Lasic, 1996).”
BackgroundInfluentialLong-circulating (sterically stabilized) liposomes for targeted drug delivery
Allen, T. M. (1994) · Trends in Pharmacological Sciences · doi:10.1016/0165-6147(94)90314-x · Cited by 445 · cited 2×
“the reticuloendothelial system (RES) and to enhance the blood retention profile (Klibanov et al, 1990, 1991; Allen, 1994; Gabizon etal, 1996; Lasic, 1996).”
BackgroundInfluential(1991) · PubMed · Cited by 418
Self-citation(1990) · PubMed · Cited by 398
Self-citationGregg, R. W., Molepo, J. M., Monpetit, V. J., Mikael, N. Z., Redmond, D., Gadia, M., & Stewart, D. J. (1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.5.795 · Cited by 358 · cited 1×
“The main neuropathy of CDDP is sensory peripheral neuropathy (van der Hoop et al, 1990; Gregg et al, 1992).”
BackgroundHorwich, A., Sleijfer, D. T., Fosså, S. D., Kaye, S. B., Oliver, R. T., Cullen, M. H., Mead, G. M., de Wit, R., de Mulder, P. H., Dearnaley, D. P., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.5.1844 · Cited by 333
Doxorubicin in sterically stabilized liposomes
Lasic, D. D. (1996) · Nature · doi:10.1038/380561a0 · Cited by 308 · cited 1×
“…93, 678 – 687 & 2005 Cancer Research UK All rights reserved 0007 – 0920/05 $30.00 www.bjcancer.com T ra n sla tio n a l T h e ra p e u tic s the reticuloendothelial system (RES) and to enhance the blood retention profile (Klibanov et al, 1990, 1991; Allen, 1994; Gabizon etal, 1996; Lasic, 1996).”
BackgroundInfluentialBoulikas, T., & Vougiouka, M. (2004) · Oncology Reports · doi:10.3892/or.11.3.559 · Cited by 287 · cited 2×
“…2005 & 2005 Cancer Research UK Keywords: cisplatin; polymeric micelle; EPR effect; neurotoxicity Cisplatin (cis-dichlorodiammineplatinum (II): CDDP) is a key drug in the chemotherapy for cancers, including lung, gastrointestinal, and genitourinary cancer (Roth, 1996; Boulikas and Vougiouka, 2004).”
BackgroundNishiyama, N., Yokoyama, M., Aoyagi, T., Okano, T., Sakurai, Y., & Kataoka, K. (1999) · Langmuir · doi:10.1021/la980572l · Cited by 259 · cited 1×
“Also, the static light scattering (SLS) measurement revealed that the CDDP-loaded micelles showed no dissociation upon dilution and the CMC was less than 5 10 7, suggesting remarkable stability compared with typical micelles from amphiphilic block copolymers (Nishiyama et al. 1999).”
MethodSelf-citationBellmunt, J., Ribas, A., Eres, N., Albanell, J., Almanza, C., Bermejo, B., Sol�, L.-A., & Baselga, J. (1997) · Cancer · doi:10.1002/(sici)1097-0142(19971115)80:10<1966::aid-cncr14>3.0.co;2-w · Cited by 228 · cited 1×
“However, those regimens including CDDP are considered to constitute the standard treatment for lung cancer, stomach cancer, testicular cancer (Horwich et al, 1997), and urothelial cancer (Bellmunt et al, 1997).”
BackgroundCisplatin-induced renal toxicity and toxicity-modulating strategies: a review
Pinzani, V., Bressolle, F., Johanne Haug, I., Galtier, M., Blayac, J. P., & Balm�s, P. (1994) · Cancer Chemotherapy and Pharmacology · doi:10.1007/bf00686277 · Cited by 217 · cited 1×
“However, we often find that it is necessary to discontinue treatment with CDDP due to its adverse reactions, for example, nephrotoxicity and neurotoxicity, despite its persisting effects (Pinzani et al, 1994).”
BackgroundSelective Delivery of Adiramycin to a Solid Tumor Using a Polymeric Micelle Carrier System
Yokoyama, M., Okano, T., Sakurai, Y., Fukushima, S., Okamoto, K., & Kataoka, K. (1999) · Journal of Drug Targeting · doi:10.3109/10611869909085500 · Cited by 213 · cited 1×
“We have recently been conducting research dedicated to the development of polymeric micelles capable of incorporating anticancer drugs (Yokoyama et al, 1990, 1991, 1999).”
BackgroundSelf-citationNishiyama, N., Kato, Y., Sugiyama, Y., & Kataoka, K. (2001) · Pharmaceutical Research · doi:10.1023/a:1010908916184 · Cited by 186 · cited 1×
“…research dedicated to the development of CDDP-incorporating polymeric micelles and have made a number of improvements, in the in vivo antitumour activity, reduction of nephrotoxicity, particle size, and particle size distribution as variables (Nishiyama and Kataoka, 2001; Nishiyama et al, 2001).”
BackgroundSelf-citationScrenci, D., McKeage, M. J., Galettis, P., Hambley, T. W., Palmer, B. D., & Baguley, B. C. (2000) · British Journal of Cancer · doi:10.1054/bjoc.1999.1026 · Cited by 180 · cited 3×
“The removed sciatic nerve was prepared for ICP-MS analysis as described previously (Screnci et al, 2000).”
MethodAnti-tumour platinum complexes : relationships between chemical properties and activity
Cleare, M. J., Hydes, P. C., Malerbi, B. W., & Watkins, D. M. (1978) · Biochimie · doi:10.1016/s0300-9084(78)80568-9 · Cited by 174 · cited 1×
“Platinum (Pt) analogues, for example, carboplatin and oxaliplatin (Cleare et al, 1978), have been developed to date to overcome these CDDP-related disadvantages.”
BackgroundCavaletti, G., Tredici, G., Marmiroli, P., Petruccioli, M. G., Barajon, I., & Fabbrica, D. (1992) · Acta Neuropathologica · doi:10.1007/bf00227662 · Cited by 164 · cited 3×
“Furthermore, histopathological examination revealed degenerative changes in the sciatic nerve in similar experimental animals (Cavaletti et al, 1992; Tredici et al, 1999).”
BackgroundMethodInfluentialNishiyama, N., & Kataoka, K. (2001) · Journal of Controlled Release · doi:10.1016/s0168-3659(01)00314-5 · Cited by 163 · cited 2×
“P(Glu) block copolymers were synthesised according to the slightly modified procedure of the previously reported synthetic method of PEG-P(Asp) (Nishiyama and Kataoka, 2001). g-Benzyl L-glutamate N-carboxy anhydride was polymerised in N,N-dimethylformamide, initiated with the NH2 amino group of…”
BackgroundMethodSelf-citationCisplatin-induced DNA-platination in experimental dorsal root ganglia neuronopathy.
Meijer, C., de Vries, E. G. E., Marmiroli, P., Tredici, G., Frattola, L., & Cavaletti, G. (1999) · PubMed · Cited by 104
Gabizon, A., Chemla, M., Tzemach, D., Horowitz, A. T., & Goren, D. (1996) · Journal of Drug Targeting · doi:10.3109/10611869608996830 · Cited by 99
Effect of Recombinant Human Nerve Growth Factor on Cisplatin Neurotoxicity in Rats
Tredici, G., Braga, M., Nicolini, G., Miloso, M., Marmiroli, P., Schenone, A. E., Nobbio, L., Frattola, L., & Cavaletti, G. (1999) · Experimental Neurology · doi:10.1006/exnr.1999.7174 · Cited by 68 · cited 2×
“Furthermore, histopathological examination revealed degenerative changes in the sciatic nerve in similar experimental animals (Cavaletti et al, 1992; Tredici et al, 1999).”
BackgroundExperimental cisplatin neuronopathy in rats and the effect of retinoic acid administration
Tredici, G., Tredici, S., Fabbrica, D., Minoia, C., & Cavaletti, G. (1998) · Journal of Neuro-Oncology · doi:10.1023/a:1005756023082 · Cited by 57
Lévi, F., Hrushesky, W. J. M., Franz Halberg, A., Langevin, T., Haus, E. L., & Kennedy, B. J. (1982) · European Journal of Cancer and Clinical Oncology · doi:10.1016/0277-5379(82)90116-x · Cited by 54 · cited 1×
“…– dose-limiting factors of CDDP, while preserving antitumour activity, which was equivalent to or better than that of free CDDP. Nephrotoxicity of CDDP is considered to depend on the peak urinary CDDP concentration and on the maximum CDDP concentration in the uriniferous tubules (Levi et al, 1982).”
BackgroundChemotherapy for advanced bladder cancer.
Roth, B. J. (1996) · PubMed · Cited by 46
McKeage, M. J., Boxall, F. E., Jones, M., & Harrap, K. R. (1994) · PubMed · Cited by 42
Neuropeptide Y and neuron-specific enolase levels in benign and malignant pheochromocytomas
Grouzmann, E., Gicquel, C., Plouin, P., Schlumberger, M. J., Comoy, E., & Bohuon, C. (1990) · Cancer · doi:10.1002/1097-0142(19901015)66:8<1697::aid-cncr2820660808>3.0.co;2-g · Cited by 36 · cited 1×
“685 British Journal of Cancer (2005) 93(6), 678 – 687& 2005 Cancer Research UK T ra n sl a ti o n a l T h e ra p e u ti c s preserved in the tail and hind paws of rats (McKeage et al, 1994; Tredici et al, 1998; Meijer et al, 1999; Tredici et al, 1999).”
BackgroundOrditura, M., Quaglia, F., Morgillo, F., Martinelli, E., Lieto, E., Rosa, G. D., Comunale, D., Diadema, M. R., Ciardiello, F., Catalano, G., et al. (2004) · Oncology Reports · doi:10.3892/or.12.3.549 · Cited by 34
(1989) · PubMed
Self-citation
Cited by
Tumor delivery of macromolecular drugs based on the EPR effect
Torchilin, V. (2011) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2010.03.011 · Cited by 2,032
Micellar Nanocarriers: Pharmaceutical Perspectives
Torchilin, V. P. (2006) · Pharmaceutical Research · doi:10.1007/s11095-006-9132-0 · Cited by 1,910
Ulbrich, K., Holá, K., Šubr, V., Bakandritsos, A., Tuček, J., & Zbořil, R. (2016) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00589 · Cited by 1,730
Mechanisms of Cisplatin Nephrotoxicity
Miller, R. P., Tadagavadi, R. K., Ramesh, G., & Reeves, W. B. (2010) · Toxins · doi:10.3390/toxins2112490 · Cited by 1,622
“, copper [68] Micellar/liposomal cisplatin [206,207] Gamma-glutamyl transpeptidase inhibitors [76,210] Glutathione transferase inhibitors [74] Anti-oxidants Amifostine [203] BNP7787 [211] N-acetyl cysteine [212] Superoxide dismutase [23,146] Catalase [149] Selenium and Vitamin E [150] Heme oxygenase-1 induction [96] I…”
BackgroundNishiyama, N., & Kataoka, K. (2006) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2006.05.006 · Cited by 1,052
Self-citation
Metadata
- Authors
- Uchino, H., Matsumura, Y., Negishi, T., Koizumi, F., Hayashi, T., Honda, T., Nishiyama, N., Kataoka, K., Naito, S., & Kakizoe, T.
- Affiliations
- National Cancer Center Hospital East (JP)
- NanoCarrier (Japan) (JP)
- Fukushima Medical University (JP)
- The University of Tokyo (JP)
- Kyushu University (JP)
- National Cancer Centre Japan (JP)
- Corresponding author
- Matsumura, Y
- Venue
- British Journal of Cancer
- Published
- 2005-09
- Volume
- 93
- Issue
- 6
- Pages
- 678-687
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- PMC
- PMC2361620
- OpenAlex
- W1974920077
- Cited by
- 430
- References
- 37
- Citations by year
- 2026: 10 · 2025: 7 · 2024: 9 · 2023: 12 · 2022: 20 · 2021: 22 · 2020: 21 · 2019: 20 · 2018: 9 · 2017: 34 · 2016: 27 · 2015: 35 · 2014: 39 · 2013: 32 · 2012: 29
- FWCI
- 5.45
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-sa
- www.springer.com/tdm (unspecified)
- Locations
- British Journal of Cancer (publishedVersion, cc-by-nc-sa)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- Ministry of Health, Labour and Welfare
- Topics
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Chemotherapy-induced organ toxicity mitigation
- Health Sciences › Medicine › Oncology › Metal complexes synthesis and properties
- Keywords
- cisplatin, polymeric micelles, nephrotoxicity, neurotoxicity, hepatotoxicity, sensory nerve conduction velocity, antitumour activity, pharmacokinetics, drug toxicity reduction
- MeSH terms
- Animals, Antineoplastic Agents, Body Weight, Brain, Cisplatin, Drug Carriers, Female, Humans, Kidney, Kidney Diseases, Liver, Mice, Inbred BALB C, Mice, Nude, Micelles, Polyethylene Glycols, Tumor Cells, Cultured, Rats, Sprague-Dawley, Neurotoxicity Syndromes, Mice, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.